These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 21154147)
1. Advances in flavivirus vaccine development. Coller BA; Clements DE; Martyak T; Yelmene M; Thorne M; Parks DE IDrugs; 2010 Dec; 13(12):880-4. PubMed ID: 21154147 [TBL] [Abstract][Full Text] [Related]
2. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Ishikawa T; Yamanaka A; Konishi E Vaccine; 2014 Mar; 32(12):1326-37. PubMed ID: 24486372 [TBL] [Abstract][Full Text] [Related]
3. Research advances in plant-made flavivirus antigens. Martínez CA; Giulietti AM; Talou JR Biotechnol Adv; 2012; 30(6):1493-505. PubMed ID: 22480936 [TBL] [Abstract][Full Text] [Related]
7. Live flavivirus vaccines: reasons for caution. Seligman SJ; Gould EA Lancet; 2004 Jun; 363(9426):2073-5. PubMed ID: 15207960 [TBL] [Abstract][Full Text] [Related]
8. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Brandler S; Tangy F Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338 [TBL] [Abstract][Full Text] [Related]
9. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Monath TP; Myers GA; Beck RA; Knauber M; Scappaticci K; Pullano T; Archambault WT; Catalan J; Miller C; Zhang ZX; Shin S; Pugachev K; Draper K; Levenbook IS; Guirakhoo F Biologicals; 2005 Sep; 33(3):131-44. PubMed ID: 15975826 [TBL] [Abstract][Full Text] [Related]
10. New developments in flavivirus vaccines with special attention to yellow fever. Pugachev KV; Guirakhoo F; Monath TP Curr Opin Infect Dis; 2005 Oct; 18(5):387-94. PubMed ID: 16148524 [TBL] [Abstract][Full Text] [Related]
11. Traditional and novel approaches to flavivirus vaccines. Pugachev KV; Guirakhoo F; Trent DW; Monath TP Int J Parasitol; 2003 May; 33(5-6):567-82. PubMed ID: 12782056 [TBL] [Abstract][Full Text] [Related]
12. Mouse and hamster models for the study of therapy against flavivirus infections. Charlier N; De Clercq E; Neyts J Novartis Found Symp; 2006; 277():218-29; discussion 229-32, 251-3. PubMed ID: 17319165 [TBL] [Abstract][Full Text] [Related]
13. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Chávez JH; Silva JR; Amarilla AA; Moraes Figueiredo LT Biologicals; 2010 Nov; 38(6):613-8. PubMed ID: 20817489 [TBL] [Abstract][Full Text] [Related]
14. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Kofler RM; Aberle JH; Aberle SW; Allison SL; Heinz FX; Mandl CW Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1951-6. PubMed ID: 14769933 [TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029 [TBL] [Abstract][Full Text] [Related]
16. Role of host cell factors in flavivirus infection: Implications for pathogenesis and development of antiviral drugs. Pastorino B; Nougairède A; Wurtz N; Gould E; de Lamballerie X Antiviral Res; 2010 Sep; 87(3):281-94. PubMed ID: 20452379 [TBL] [Abstract][Full Text] [Related]
17. Dengue and other emerging flaviviruses. Solomon T; Mallewa M J Infect; 2001 Feb; 42(2):104-15. PubMed ID: 11531316 [TBL] [Abstract][Full Text] [Related]
18. Current status of flavivirus vaccines. Barrett AD Ann N Y Acad Sci; 2001 Dec; 951():262-71. PubMed ID: 11797783 [TBL] [Abstract][Full Text] [Related]